BORJE S ANDERSSON to Tumor Cells, Cultured
This is a "connection" page, showing publications BORJE S ANDERSSON has written about Tumor Cells, Cultured.
Connection Strength
0.486
-
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma. 2017 11; 58(11):2705-2716.
Score: 0.087
-
Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res. 2016 08; 47:100-8.
Score: 0.082
-
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma. 2016 11; 57(11):2644-52.
Score: 0.081
-
Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res. 2008 Nov; 32(11):1684-97.
Score: 0.046
-
Model studies of cyclophosphamide resistance in human myeloid leukemia. Cancer Treat Res. 2002; 112:211-35.
Score: 0.030
-
Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line. Leuk Res. 1998 Nov; 22(11):1073-7.
Score: 0.024
-
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia. 1995 Dec; 9(12):2100-8.
Score: 0.020
-
Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. Acta Oncol. 1995; 34(2):247-51.
Score: 0.019
-
The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues. Cancer Res. 1994 Oct 15; 54(20):5394-400.
Score: 0.018
-
KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol. 1992 Mar; 20(3):361-7.
Score: 0.015
-
Suitability of a new stable acetal analogue of aldoifosphamide for purging leukemic cells from human bone marrow. Leukemia. 1990 Jun; 4(6):435-40.
Score: 0.014
-
DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells. Cancer Biochem Biophys. 1990 Jan; 11(1):23-30.
Score: 0.013
-
Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia. Br J Cancer. 1990 Jan; 61(1):51-5.
Score: 0.013
-
Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis. 1996 Mar; 121(1):93-103.
Score: 0.005
-
p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro. Cancer Genet Cytogenet. 1995 Jul 01; 82(1):35-40.
Score: 0.005
-
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993 Aug 01; 53(15):3603-10.
Score: 0.004
-
Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
Score: 0.004
-
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells. Biochem Pharmacol. 1987 Dec 01; 36(23):4067-77.
Score: 0.003
-
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia. 1987 Jan; 1(1):52-7.
Score: 0.003